Login to Your Account



Mologen shares rise on MGN1703 survival data in CRC patients

By Cormac Sheridan
Staff Writer

Wednesday, July 2, 2014
Shares in Mologen AG rose 13 percent Monday on interim survival data indicating that a small subgroup of patients with metastatic colorectal cancer experienced lengthy – and ongoing – progression-free survival (PFS) with cancer immunotherapy MGN1703.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription